AcelRx Pharma (ACRX) Reports In-Line Q4 EPS

March 8, 2018 4:15 PM

AcelRx Pharma (NASDAQ: ACRX) reported Q4 EPS of ($0.20), in-line with the analyst estimate of ($0.20). Revenue for the quarter came in at $740 thousand versus the consensus estimate of $5.25 million.

Financial Information

2018 Guidance and Expected Upcoming MilestonesAcelRx expects quarterly net cash usage in 2018 to remain in the $10-11 million range before initiating pre-launch commercialization investments, which are planned to ramp after obtaining FDA approval of DSUVIA. This upcoming year has many key milestones for AcelRx, including:

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.


Earnings Guidance

Next Articles